Evaluation the validity of metalloproteinase 9 in Nephrotic Syndrome patients in AlNajaf province

¹ Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Najaf, Iraq
² University of Kufa, Najaf, Iraq

^* Corresponding author: alaa.a.kadham@jmu.edu.iq

Abstract

Background: Nephrotic syndrome is a medical disorder characterized by large proteinuria (more than 40 mg/m^2 hourly) that causes hypoalbuminemia (below than 30 g/L), which leads to edema, hyperlipidemia, and additional complications. The renal glomerulus’s Injured basement membrane causes increased permeability, A variation in glomerular permeability is the cause of this condition. Materials and methods: 70 patients were randomly chosen to participate in the clinical study. (35 Males and 35 Females) with autoimmune disease and nephrotic syndrom attending the kidney disease center in AlSadder Teaching City in AlNajaf province, Iraq. It was carried out from November 2022 to July 2023. The ages of patients was range of 1-50y. Results: The consequences show asignificant decrease (P≤ 0.05) in Metalloproteinase -9 (MMP9) level in nephrotic patients in relating with control groups moreover demonstrate a significant decline (P≤ 0.05) in metalloproteinase -9 (MMP9) level in nephrotic patients in compare with control group at different age groups and results furthermore display significant effect (p≥ 0.05) in metalloproteinase -9 (MMP9) level between groups of ages also reveal no significant effect (P≥ 0.05) in metalloproteinase 9 in females and males in nephrotic patients and significant reduction (P≤ 0.05) in metalloproteinase 9level in both nephrotic patients in comparing with control groups. show a significant increase (P≤ 0.05) in Metalloproteinase -9 (MMP9) level in nephrotic patients in rural groups than urban groups. Conclusion: The present study concluded that was found significantly decreased in nephrotic patient and increased in rural nephrotic patients than in urban patients.